This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Houghtaling, S. Articles by Grompe, M. Search for Related Content PubMed PubMed Citation Articles by Houghtaling, S. Articles by Grompe, M.

Heterozygosity for p53 (Trp53^+/–) Accelerates Epithelial Tumor Formation in Fanconi Anemia Complementation Group D2 (Fancd2) Knockout Mice

¹ Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon and ² Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas

Requests for reprints: Scott Houghtaling, Department of Molecular and Medical Genetics, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code L103, Portland, OR 97239. Phone: 503-494-6206. E-mail: houghtal{at}ohsu.edu

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure and an increased susceptibility to cancer. FA is genetically heterogeneous, consisting of at least 11 complementation groups, FA-A through L, including FA-D1 (BRCA2) and D2. We have previously reported an increased incidence of epithelial tumors in Fancd2 knockout mice. To further investigate the role of the FA pathway in tumor prevention, Fancd2 mutant mice were crossed to mice with a null mutation in the tumor suppressor gene, Trp53. The tumor spectrum in Fancd2^–/–/Trp53^+/– mice included sarcomas expected in Trp53 heterozygotes, as well as mammary and lung adenocarcinomas that occur rarely in Trp53 heterozygotes. These tumors occurred earlier than in Fancd2^–/– control mice. Therefore, the Fancd2^–/–/Trp53^+/– mice represent an improved model for the study of adenocarcinoma in FA. In addition, it was found that Fancd2^–/– mouse embryonic fibroblasts but not Fancd2^–/–/Trp53^–/– mouse embryonic fibroblasts arrest following DNA damage. Therefore, Trp53 is required for the S phase checkpoint activation observed in Fancd2 mutant cells. Fancd2^–/–/Trp53^–/– cells showed an increase in aneuploidy and had multiple gross chromosomal rearrangements.

Key Words: Fanconi anemia • Fancd2 • Trp53 • Mammary Adenocarcinoma

This article has been cited by other articles:

				Q.-S. Zhang, L. Eaton, E. R. Snyder, S. Houghtaling, J. B. Mitchell, M. Finegold, C. Van Waes, and M. Grompe Tempol Protects against Oxidative Damage and Delays Epithelial Tumor Onset in Fanconi Anemia Mice Cancer Res., March 1, 2008; 68(5): 1601 - 1608. [Abstract] [Full Text] [PDF]

				N. Spardy, A. Duensing, D. Charles, N. Haines, T. Nakahara, P. F. Lambert, and S. Duensing The Human Papillomavirus Type 16 E7 Oncoprotein Activates the Fanconi Anemia (FA) Pathway and Causes Accelerated Chromosomal Instability in FA Cells J. Virol., December 1, 2007; 81(23): 13265 - 13270. [Abstract] [Full Text] [PDF]

				E. Barroso, R.L. Milne, L.P. Fernandez, P. Zamora, J.I. Arias, J. Benitez, and G. Ribas FANCD2 associated with sporadic breast cancer risk Carcinogenesis, September 1, 2006; 27(9): 1930 - 1937. [Abstract] [Full Text] [PDF]

				T. Taniguchi and A. D. D'Andrea Molecular pathogenesis of Fanconi anemia: recent progress Blood, June 1, 2006; 107(11): 4223 - 4233. [Abstract] [Full Text] [PDF]

				R. D. Kennedy and A. D. D'Andrea The Fanconi Anemia/BRCA pathway: new faces in the crowd Genes & Dev., December 15, 2005; 19(24): 2925 - 2940. [Abstract] [Full Text] [PDF]